Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis

@article{Reis2019BimekizumabTF,
  title={Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis},
  author={Joel Reis and Ronald B. Vender and Tiago Torres},
  journal={BioDrugs},
  year={2019},
  pages={1-9}
}
Psoriasis is a chronic inflammatory skin disease with significant psychological and physical impact. Over the last few decades, several highly effective target therapies have been developed, leading to a major paradigm shift in the way psoriatic disease is managed. Despite this, a proportion of patients still do not respond or lose response over time. Bispecific antibodies target two different cytokines simultaneously, potentially offering a better disease control. Interleukin (IL)-17A and IL… 
Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis
TLDR
Clinical trials of bimekizumab have been promising, demonstrating a rapid onset of response and superior efficacy than three of the currently licensed biologics: secukinumab, ustekinumAB, and adalimumab.
Dual inhibition of IL-17A and IL-17F in psoriatic disease
TLDR
Current evidence on bimekizumab and sonelokimab is reviewed, finding that dual inhibitor and bispecific antibodies simultaneously targeting IL-17A andIL-17F could provide better disease control.
An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far
TLDR
The evidence so far for the use in psoriatic arthritis of bimekizumab, the first humanized monoclonal IgG1 antibody that selectively neutralizes both IL-17A and IL- 17F is reviewed.
Bimekizumab for the Treatment of Psoriasis
TLDR
The results obtained in the phase 3 studies corroborate the high levels of efficacy of bimekizumab seen in previous studies, and show superior efficacy over adalimumab, ustekinumab, and secuk inumab in direct comparative studies.
Novel concepts in psoriasis: histopathology and markers related to modern treatment approaches
  • Carina Mihu, M. Neag, A. Buzoianu
  • Biology, Medicine
    Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • 2021
TLDR
An up-to-date briefing of psoriasis histopathology and pharmacogenetic factors that are considered for the accurate evaluation of treatment response is done.
Preliminary Report on Interleukin-22, GM-CSF, and IL-17F in the Pathogenesis of Acute Anterior Uveitis
TLDR
A novel multi-parametric flow cytometry panel to identify immune dysregulation signatures in HLA B27-associated acute anterior uveitis and axial spondyloarthritis is developed, arguably the first to implicate IL-17F or ILC-3 and MAIT cells in the pathogenesis of AAU.
Interleukin 17A Promotes Cell Migration, Enhances anoikis resistance, and Favors Microenvironment for Triple Negative Breast Cancer Tumor Metastasis
TLDR
It is concluded that IL-17A promotes migratory and angiogenic activity in the tumors, enhances anoikis resistance, and modulates the immune landscape of tumor microenvironment favoring subsequent cancer metastasis.
Notch-Hes1 Signaling Regulates IL-17A+γδ+T Cell Expression and IL-17A Secretion of Mouse Psoriasis-Like Skin Inflammation
TLDR
In vitro study demonstrated that DAPT treatment could result in dose-dependent decrease of IL- 17A+γδ+T cell percentage and IL-17A secretion in splenic single cells of model mice.
Interleukin 17A promotes cell migration, enhances anoikis resistance, and creates a microenvironment suitable for triple negative breast cancer tumor metastasis
TLDR
It is concluded that IL-17A promotes migratory and angiogenic activity in tumors, enhances anoikis resistance, and modulates the immune landscape of the tumor microenvironment such changes favor cancer metastasis.
...
...

References

SHOWING 1-10 OF 56 REFERENCES
AB0738 DUAL NEUTRALISATION OF INTERLEUKIN (IL)–17A AND IL–17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY
TLDR
Bimekizumab provided rapid and substantial clinical improvements in patients with moderate-to-severe plaque psoriasis, with a safety profile consistent with previous bimekuzumab studies, and nearly all BE aBLE 1 responders completing 60 weeks of bIMEkizumsab treatment maintained complete or almost complete skin clearance.
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation
TLDR
IL-17F is supported as a key driver of human chronic tissue inflammation and the rationale for dual neutralisation of IL-17A and IL- 17F in PsA and related conditions is supported.
Anti-IL17 therapies for psoriasis
TLDR
The development and approval of the IL-17 inhibitor agents secukinumab, ixekizuab, and brodalumab has expanded psoriatic treatment with effective options, validating the importance of the pro-inflammatory role of IL- 17 psoriasis pathophysiology.
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
TLDR
The current knowledge around the cytokines belonging to the IL-17 family in relation to skin inflammation in general and psoriasis in particular is summarized, possible clinical implications are discussed, and a comprehensive understanding of the different roles played by theIL-17 cytokines are discussed.
LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study
TLDR
The primary and key secondary objectives were achieved and a greater percentage of bimekizumab-treated patients achieved ASAS40 (primary endpoint) than placebo (Figure: p<0.001, all doses); no unexpected safety risks were observed; the most frequently reported events were nasopharyngitis and headache.
The role of IL 23 in the treatment of psoriasis
  • L. Puig
  • Biology, Medicine
    Expert review of clinical immunology
  • 2017
TLDR
Specific IL-23p19 blockade with high-affinity monoclonal antibodies seems to be able to induce long-term remissions of the activity in psoriasis and might eventually represent a paradigm change in the treatment of psorosis.
Ultra-Sensitive Measurement of IL-17A and IL-17F in Psoriasis Patient Serum and Skin
TLDR
Ultrasensitive methods for measuring IL-17A andIL-17F in human serum samples are developed and it is found that serum from psoriasis patients had higher and a broader range of concentrations of both IL- 17 proteins compared to healthy volunteers.
Interleukin‐17A: a unique pathway in immune‐mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis
TLDR
Experimental evidence points to the importance of the cytokine interleukin‐17A in the pathogenesis of several immunoinflammatory diseases including psoriasis, psoriatic arthritis and rheumatoid arthritis, although levels of response are not predicted by pre‐clinical findings.
Involvement of IL-17F via the induction of IL-6 in psoriasis
TLDR
The results indicate that IL-17F produced by CD4+ T cells causes the inflammation in psoriasis partly through induction of IL-6 in keratinocytes.
...
...